このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Spyre Therapeutics マネジメント

マネジメント基準チェック /04

Spyre Therapeutics'の CEO はCameron Turtleで、 Oct2023年に任命され、の在任期間は 1 年未満です。の年間総報酬は$ 16.17Mで、 1.7%給与と98.3%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.47%を直接所有しており、その価値は$ 20.80M 。経営陣と取締役会の平均在任期間はそれぞれ0.9年と1.2年です。

主要情報

Cameron Turtle

最高経営責任者

US$16.2m

報酬総額

CEO給与比率	1.7%
CEO在任期間	less than a year
CEOの所有権	1.5%
経営陣の平均在職期間	less than a year
取締役会の平均在任期間	1.2yrs

経営陣の近況

Recent updates

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Feb 24

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Oct 28

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Aug 18

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aug 04

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Jun 09

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Dec 07

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aug 10

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aug 08

Aeglea BioTherapeutics EPS misses by $0.14

May 10

Aeglea completes patient randomization in late-stage pegzilarginase trial

May 03

What You Need To Know About Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) Investor Composition

Mar 17

We Think Aeglea BioTherapeutics (NASDAQ:AGLE) Needs To Drive Business Growth Carefully

Feb 10

CEO報酬分析

Spyre Therapeutics の収益と比較して、Cameron Turtle の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$186m
Mar 31 2024	n/a	n/a	-US$364m
Dec 31 2023	US$16m	US$273k	-US$339m

報酬と市場: Cameronの総報酬 ($USD 16.17M ) は、 US市場 ($USD 5.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Cameronの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Cameron Turtle (34 yo)

less than a year

在職期間

US$16,174,660

報酬

Dr. Cameron Turtle, D.Phil. & Ph D., joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executiv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Cameron Turtle	CEO & Director	less than a year	US$16.17m	1.47% $ 19.8m
Scott Burrows	Chief Financial Officer	less than a year	US$7.55m	0% $ 0
Heidy King-Jones	Chief Legal Officer & Corporate Secretary	less than a year	US$6.93m	0% $ 0
Janet Gunzner-Toste	Senior Vice President of Operations	no data	データなし	データなし
Brian Connolly	Chief Technical Officer	less than a year	データなし	データなし
Eric McIntyre	Vice President of Finance & Investor Relations	no data	データなし	データなし
James Myers	Vice President of Quality & Compliance	no data	データなし	データなし
Kelly Boothe	Senior Director of Corporate Communications & Investor Relations	no data	データなし	データなし
Justin LaFountaine	Senior Vice President of Corporate Development	no data	データなし	データなし
Melissa Cooper	Senior Vice President of People	no data	データなし	データなし
James Kastenmayer	Consultant	1.3yrs	US$865.79k	データなし
Joshua Friedman	Senior Vice President of Clinical Development	less than a year	データなし	データなし

0.9yrs

平均在職期間

44yo

平均年齢

経験豊富な経営陣: SYREの経営陣は経験豊富とはみなされません ( 0.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Cameron Turtle	CEO & Director	less than a year	US$16.17m	1.47% $ 19.8m
Daniel Von Hoff	Member of Scientific Advisory Board	7.9yrs	データなし	データなし
Matthew Vander Heiden	Member of Scientific Advisory Board	7.9yrs	データなし	データなし
Keith Flaherty	Member of Scientific Advisory Board	7.9yrs	データなし	データなし
Jeffrey Albers	Independent Chairman of the Board	less than a year	US$433.57k	0.068% $ 913.0k
Arthur Frankel	Member of Scientific Advisory Board	7.9yrs	データなし	データなし
Wayne Klohs	Member of Scientific Advisory Board	7.9yrs	データなし	データなし
Tomas Kiselak	Independent Director	1.2yrs	US$658.43k	0.80% $ 10.8m
Mark McKenna	Independent Director	less than a year	データなし	0% $ 0
Laurie Stelzer	Independent Director	less than a year	US$434.38k	0% $ 0
Michael Henderson	Independent Director	1.2yrs	US$660.78k	0% $ 0
Peter Harwin	Independent Director	1.2yrs	US$661.28k	0.80% $ 10.8m

1.2yrs

平均在職期間

44yo

平均年齢

経験豊富なボード: SYREの取締役会は経験豊富ではない ( 1.2年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Spyre Therapeutics マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Recent updates

Spyre Therapeutics, Inc. Announces First Participants Dose in Phase 1 Trial of SPY001

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc., Annual General Meeting, May 13, 2024

Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. Announces Board Changes

Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors

Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors

Spyre Therapeutics, Inc.(NasdaqCM:SYRE) dropped from NASDAQ Composite Index

Aeglea BioTherapeutics, Inc. Announces Appointment of Cameron Turtle as Principal Executive Officer

Aeglea Biotherapeutics, Inc. Regains Compliance with Nasdaq Listing Rule

Aeglea Biotherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Immedica Pharma signed an agreement to acquire global rights to pegzilarginase from Aeglea BioTherapeutics, Inc from Aeglea BioTherapeutics, Inc. (NasdaqCM:AGLE) for $115 million.

Aeglea Biotherapeutics Receives Approval from Nasdaq of the Transfer of the Listing of Its Common Stock from Nasdaq Global Market to the Nasdaq Capital Market

High number of new directors

Aeglea BioTherapeutics, Inc. announced that it expects to receive $210.000248 million in funding from a group of investors

Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE) acquired Spyre Therapeutics, Inc. for $1.42 million.

New major risk - Share price stability

Aeglea Biotherapeutics, Inc. Announces the Termination of Jeffrey Goldberg as Chief Executive Officer

Aeglea BioTherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 48%

Price target increased by 20% to US$3.12

Consensus EPS estimates upgraded to US$0.61 loss

Price target decreased by 16% to US$2.27

No longer forecast to breakeven

Aeglea BioTherapeutics (NASDAQ:AGLE) Will Have To Spend Its Cash Wisely

Aeglea BioTherapeutics Receives Written Notice from The Nasdaq Stock Market, LLC Regarding Minimum Bid Price Requirement for Continued Listing

Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating Officer

Aeglea Biotherapeutics, Inc. Announces Chief Executive Officer Changes

Aeglea BioTherapeutics, Inc. Appoints Linda Neuman as Chief Medical Officer

Price target increased to US$2.70

Consensus forecasts updated

Price target increased to US$2.70

We're A Little Worried About Aeglea BioTherapeutics' (NASDAQ:AGLE) Cash Burn Rate

Aeglea BioTherapeutics, Inc. Provides Clinical Progress and Regulatory Update for Homocystinuria Program

Insider recently bought US$50k worth of stock

Aeglea Biotherapeutics Announces Leadership Transition

Aeglea BioTherapeutics, Inc. Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea stock jumps ~58% after hours on European nod for enzyme pegzilarginase

Consensus forecasts updated

Aeglea BioTherapeutics GAAP EPS of -$0.27 beats by $0.04, revenue of $0.63M misses by $0.08M

Aeglea BioTherapeutics Receives Non-Compliance Notice from Nasdaq

Aeglea BioTherapeutics Announces Resignation of Sandesh Mahatme as Director

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2000 Dynamic Index

Can Aeglea BioTherapeutics (NASDAQ:AGLE) Afford To Invest In Growth?

Aeglea Biotherapeutics, Inc. Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Consensus revenue estimates increase by 36%

Price target decreased to US$9.86

Price target decreased to US$11.00

Aeglea BioTherapeutics, Inc. Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at SIMD

Consensus revenue estimates increase by 76%

President recently bought US$281k worth of stock

Consensus forecasts updated

Price target decreased to US$11.00

Aeglea Biotherapeutics, Inc. Announces Resignation of Sara Brownstein as Class I Director of the Board

Independent Director recently bought US$550k worth of stock

Aeglea BioTherapeutics, Inc. Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency

Price target decreased to US$12.43

Aeglea Presents Itself As Buy Opportunity After Latest Data Causes Stock To Trade Lower

Chief Financial Officer recently bought US$263k worth of stock

Consensus revenue estimates increase to US$17.9m

Industry Analysts Just Made A Stunning Upgrade To Their Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Revenue Forecasts

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates

Aeglea BioTherapeutics, Inc. Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for Treatment of Arginase 1 Deficiency in Journal of Inherited Metabolic Disease

Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped from Russell 2500 Growth Index

Aeglea Biotherapeutics Doses First Patient in A Phase 1/2 Clinical Trial of Agle-177, A Potential First-In-Class Treatment for Homocystinuria

Aeglea BioTherapeutics EPS misses by $0.14

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency

マネジメント基準チェック /04